Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.